Survival boost for Votrient in mRCC
GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free survival (PFS).
In the open-label, head-to-head Phase III study COMPARZ, advanced renal cell carcinoma (mRCC) patients treated with Votrient (pazopanib) had a similar PFS to those in the Sutent (sunitinib) arm.
The news confirms Votrient’s status in this therapy area: Sutent is still the market leader but Votrient is challenging hard, and will usurp Sutent by 2016, according to analysts at Decision Resources.
In the COMPARZ trial, whose primary endpoint was PFS, the Votrient versus Sutent hazard ratio for PFS was 1.047 (95% CI 0.898, 1.220) and the predefined criterion for non-inferiority was the upper bound of a two-sided 95% CI of 1.25.
Median PFS was 8.4 months (95% CI 8.3, 10.9) for Votrient compared to Sutent at 9.5 months (95% CI 8.3, 11.1), according to data presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
In the study, 1,110 patients were randomised to receive treatment with either drug at their respective, approved treatment doses for four weeks followed by two weeks off treatment.
Treatment continued in both arms until patients showed signs of disease progression, unacceptable toxicity or voluntarily withdrew.
The secondary endpoint showed an objective response rate of 31% in the Votrient arm compared to 25% in the Sutent arm.
Paolo Paoletti, president of GSK Oncology, said: “There has been limited in